We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF- , family of proteins. We are a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair …
27.71% operating margin is above average. ROIC at 13.77%.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$33M
Net Income (TTM)
-$85M
▲ +146.4% YoY
Op. Margin
-337.41%
ROIC
-16.86%
▲ +49.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$58M
▲ +165.1% YoY
Op. Cash Flow (TTM)
-$57M
▲ +166.8% YoY
Net Debt
-$265M
Net Cash Position
Cash & Equiv.
$281M
Continue Research